Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Royalty Pharma PLC | RPRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 26.61 | 03:00:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 26.61 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 25.92 - 31.93 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 26.61 | USD |
Royalty Pharma PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.9B | 597.43M | - | 2.35B | 1.13B | 1.90 | 14.01 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Royalty Pharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/10/2024 | 15:58 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/06/2024 | 16:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/04/2024 | 16:12 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 6/04/2024 | 15:57 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/04/2024 | 15:15 | GlobeNewswire Inc. | Royalty Pharma to Present at the Goldman Sachs 45th Annual.. |
| 6/03/2024 | 16:15 | GlobeNewswire Inc. | Royalty Pharma Announces Pricing of $1.5 Billion of Senior.. |
| 6/03/2024 | 15:59 | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free.. |
| 6/03/2024 | 08:13 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 6/03/2024 | 07:39 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of.. |
| 5/29/2024 | 16:25 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/28/2024 | 06:10 | GlobeNewswire Inc. | Royalty Pharma and Agios Pharmaceuticals Enter Into.. |
| 5/22/2024 | 15:10 | GlobeNewswire Inc. | Royalty Pharma and Cytokinetics Announce Expanded Strategic.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 27.35 | 27.60 | 26.455 | 27.09 | 2,010,694 | -0.74 | -2.71% |
| 1 Month | 27.33 | 27.695 | 26.105 | 27.01 | 2,697,583 | -0.72 | -2.63% |
| 3 Months | 30.22 | 30.80 | 26.105 | 27.97 | 2,681,882 | -3.61 | -11.95% |
| 6 Months | 27.45 | 31.655 | 26.105 | 28.71 | 2,651,343 | -0.84 | -3.06% |
| 1 Year | 31.93 | 31.93 | 25.92 | 28.71 | 2,484,853 | -5.32 | -16.66% |
| 3 Years | 43.91 | 44.75 | 25.92 | 35.31 | 2,165,905 | -17.30 | -39.40% |
| 5 Years | 45.90 | 57.50 | 25.92 | 37.79 | 2,157,429 | -19.29 | -42.03% |
Royalty Pharma Description
| Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |
